Hisamitsu Pharmaceutical Co. Inc. announced consolidated and non-consolidated earnings results for the first quarter ended May 2016. For the quarter, on consolidated basis, the company's sales were ¥38,153 million compared with ¥39,680 million a year ago. Operating profits were ¥5,744 million compared with ¥5,737 million a year ago. Recurring profits were ¥5,561 million compared with ¥5,663 million a year ago. Pretax profits were ¥6,859 million compared with ¥5,639 million a year ago. Net profits were ¥4,529 million compared with ¥3,535 million a year ago.

For the quarter, on non-consolidated basis, the company's sales were ¥28,436 million compared with ¥28,867 million a year ago. Operating profits were ¥4,598 million compared with ¥5,695 million a year ago. Recurring profits were ¥4,656 million compared with ¥6,108 million a year ago. Pretax profits were ¥5,959 million compared with ¥6,093 million a year ago. Net profits were ¥4,195 million compared with ¥4,069 million a year ago.

For the year ending February 2017, the company forecasts consolidated sales of ¥155,000 million, operating profits of ¥28,000 million, pretax profits of ¥30,300 million, net profits of ¥19,400 million, capex of ¥5,300 million, depreciation of ¥5,500 million, and goodwill amortization of ¥2,100 million.

The company forecasts non-consolidated sales of ¥119,500 million, operating profits of ¥24,500 million, pretax profits of ¥26,800 million, net profits of ¥18,000 million, capex of ¥3,700 million, depreciation of ¥3,000 million, and goodwill amortization of ¥1,100 million.